Table 1.
Patient Characteristics: Success versus Failure (C-ETGBD)
| Characteristics | 2008–2020 (n=101) | Success (n=73) | Failure (n=28) | p-value |
|---|---|---|---|---|
| Age, yr | 77 (40–96) | 76 (40–96) | 79 (59–94) | 0.126 |
| Sex, M/F | 64/37 | 45/28 | 19/9 | 0.562 |
| Cholecystitis | 0.118 | |||
| Mild | 63 (62.4) | 50 (68.5) | 13 (46.4) | |
| Moderate | 27 (26.7) | 16 (21.9) | 11 (39.3) | |
| Severe | 11 (10.9) | 7 (9.6) | 4 (14.3) | |
| WBC, ×103/µL | 11.5±5.50 | 11.3±4.92 | 12.1±7.02 | 0.538 |
| CRP, mg/dL | 11.6±7.91 | 11.5±7.91 | 12.8±8.17 | 0.482 |
| GB stone | 76 (75.2) | 54 (74.0) | 22 (78.6) | 0.632 |
| Background to challenge ETGBD | ||||
| Comorbidity with CBD stone | 58 (57.4) | 42 (57.5) | 16 (57.1) | 0.972 |
| Antithrombotic agents | 20 (19.8) | 14 (19.2) | 6 (21.4) | 0.799 |
| Comorbidity with suspected GB cancer | 13 (12.9) | 11 (15.1) | 2 (7.1) | 0.287 |
| Dementia | 20 (19.8) | 11 (15.1) | 9 (32.1) | 0.064 |
| Ascites | 12 (11.9) | 8 (11.0) | 4 (14.3) | 0.644 |
| Papilla | 0.421 | |||
| Naïve | 64 (63.4) | 48 (65.8) | 16 (57.1) | |
| Post-EST | 37 (36.6) | 25 (34.2) | 12 (42.9) |
Data are presented as median (range), number (%), or mean±SD.
ETGBD, endoscopic transpapillary gallbladder drainage; C-ETGBD, conventional ETGBD; M, male; F, female; WBC, white blood cell; CRP, C-reactive protein; GB, gallbladder; CBD, common bile duct; EST, endoscopic sphincterotomy.